Skip to main content
. 2021 Mar 12;23(5):355. doi: 10.3892/mmr.2021.11994

Figure 5.

Figure 5.

Effect of anti-HLAI on IL-8, MCP-1, vWF and anti-TGF-β1, and the impact of halofuginone or everolimus treatment. (A) Anti-HLAI antibodies increased IL-8. Halofuginone or everolimus decreased anti-HLAI-induced IL-8 upregulation. (B) Anti-HLAI antibodies enhanced MCP-1. Halofuginone or everolimus reduced anti-HLAI-induced MCP-1 production. (C) Anti-HLAI antibodies increased vWF. Halofuginone did not affect vWF, while everolimus prevented anti-HLAI-induced vWF upregulation. (D) Anti-HLAI antibodies raised the TGF-β1 level. Halofuginone or everolimus suppressed anti-HLAI-induced TGF-β1 production. Data are presented as the mean ± SEM. The superscripts *P<0.05 vs. control cells, #P<0.05 vs. anti-HLAI-treated cells, ^P<0.05 vs. anti-HLAI-treated cells administered halofuginone, +P<0.05 vs. anti-HLAI-treated cells administered everolimus and $P<0.05 vs. anti-HLAI-treated cells with halofuginone and everolimus. HLAI, human leukocyte antigen class I; MCP-1, monocyte chemoattractive protein-1; vWF, von Willebrand factor; Hal, halofuginone; Ever, everolimus; Ctrl, control.